After 722, 25 products got NDA application; We are number one in the industry, which proved that our quality is consistent.

We are responsible for the development of hepatitis drugs in China,  and the most popular PD-1/PD-L1 immune tumor experiment to undertake 50+.

Through high quality service, we have won unanimous praise from the sponsors, investgators and CRO partners, and the repeat business rate is up to 90%.

Audit by top 10 global pharmaceutical companies and 5 global CROs

100+ studies were inspected by NMPA

2 projects were inspected by EMA,5 project was inspected by FDA

 

 

Copyright © 2014-2018 SMO ClinPlus Co., Ltd.
F23, No.333 Finance Square, Jiujiang Road, Huangpu District, Shanghai, China 200001 Privacy